Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Minerva Endocrinologica
|
December 9, 1998
IGF-I levels in prepubertal and pubertal children with Down syndrome
L Ragusa, M R Valetto, C Proto, et al.
Cancer Treatment Reviews
|
November 19, 2025
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies
D Miliziano, C Sciortino, S Manglaviti, et al.
Journal of Endocrinological Investigation
|
January 2, 2003
Twenty-four-hour urinary cortisol levels in Alzheimer disease and in mild cognitive impairment
R S Spada, R M Cento, C Proto, et al.
Archives of Gerontology and Geriatrics. Supplement
|
February 7, 2004
Twenty-four-hour urinary cortisol levels in Alzheimer disease and in dysthymia
R S Spada, R M Cento, C Proto, et al.
ESMO Real World Data and Digital Oncology
|
April 3, 2026
Corrigendum to "Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of <i>EGFR</i>-mutated advanced NSCLC patients": [ESMO Real World Data and Digital Oncology Volume 10, December 2025, 100198]
F Corso, P Baili, F Scotti, et al.
Cancer Treatment Reviews
|
April 8, 2019
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out
C Proto, R Ferrara, D Signorelli, et al.
ESMO Open
|
December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
G Lo Russo, F Sgambelluri, A Prelaj, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records
L Mazzeo, F Corso, P Baili, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2023
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
A Prelaj, V Miskovic, M Zanitti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
F de Marinis, T M Kim, L Bonanno, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Minerva Endocrinologica
|
December 9, 1998
IGF-I levels in prepubertal and pubertal children with Down syndrome
L Ragusa, M R Valetto, C Proto, et al.
Cancer Treatment Reviews
|
November 19, 2025
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies
D Miliziano, C Sciortino, S Manglaviti, et al.
Journal of Endocrinological Investigation
|
January 2, 2003
Twenty-four-hour urinary cortisol levels in Alzheimer disease and in mild cognitive impairment
R S Spada, R M Cento, C Proto, et al.
Archives of Gerontology and Geriatrics. Supplement
|
February 7, 2004
Twenty-four-hour urinary cortisol levels in Alzheimer disease and in dysthymia
R S Spada, R M Cento, C Proto, et al.
ESMO Real World Data and Digital Oncology
|
April 3, 2026
Corrigendum to "Cost-effectiveness of first-line osimertinib informed by electronic medical records via text-mining: a real-world Italian case study of <i>EGFR</i>-mutated advanced NSCLC patients": [ESMO Real World Data and Digital Oncology Volume 10, December 2025, 100198]
F Corso, P Baili, F Scotti, et al.
Cancer Treatment Reviews
|
April 8, 2019
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out
C Proto, R Ferrara, D Signorelli, et al.
ESMO Open
|
December 1, 2022
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
G Lo Russo, F Sgambelluri, A Prelaj, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records
L Mazzeo, F Corso, P Baili, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 25, 2023
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
A Prelaj, V Miskovic, M Zanitti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2025
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
F de Marinis, T M Kim, L Bonanno, et al.
Page
of 8